Track topics on Twitter Track topics that are important to you
Sanofi will develop Principia Biopharma’s Phase I central nervous system (CNS) candidate PRN2246 as a treatment for multiple sclerosis (MS), through a collaboration that could generate up to $805 million for Principia, the companies said today. PRN2246 is a low-dose, covalent Bruton's tyrosine kinase (BTK) inhibitor that can cross the blood–brain barrier to access the brain and spinal cord, enabling the drug to penetrate the CNS with the goal of effectively and safely modulate B-cell function without depleting B cells. According to Principia, the role of B cells in autoimmunity has been clinically validated with B-cell-depleting therapy in MS and other diseases that affect the nervous system. Principia recently launched a Phase I trial of PRN2246 in healthy volunteers. “Sanofi is an ideal partner for PRN2246,” Principia CEO Martin Babler said in a statement. “The agreement allows Principia to maximize the BTK opportunity in neurology with ...NEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...